Indivior Plans to Cancel London Listing After Moving Primary to US

Indivior Plc plans to cancel its secondary listing in London, following its primary listing shift to New York last year. The opioid-addiction therapy maker is making the move to better align its listing with its revenue streams and investor base, as the majority of its trading volume now originates in the U.S. This decision also aims to reduce the costs associated with maintaining a secondary listing.

Analysis

Indivior Plc has announced its intention to cancel its secondary listing on the London Stock Exchange, a move that follows the transition of its primary listing to the US approximately one year ago. The opioid-addiction therapy maker justifies this decision by citing a desire to more accurately reflect its primary revenue geography, eliminate the costs associated with maintaining a secondary listing, and acknowledge that the majority of its trading volume and investor base are now concentrated in the US. This consolidation effort comes after an initial period described as a "rocky start" in the US market, marked by guidance cuts, following the primary listing shift which was originally pursued to gain enhanced analyst and investor coverage. Indivior's move is noted as the latest departure from the UK’s capital markets. The neutral overall sentiment, with a slightly positive ticker-specific sentiment for INDV, suggests this delisting is viewed primarily as a practical corporate streamlining measure aimed at operational efficiency, rather than a fundamental strategic shift with immediate, significant positive or negative implications beyond modest cost savings.

Key Decisions for Investors

• Investors holding Indivior shares on the London Stock Exchange should prepare for the delisting and ensure they have access to its primary US listing for future trading activity.
• Close monitoring of Indivior's operational performance and financial guidance on its US exchange is crucial, particularly recalling the "rocky start" and previous guidance cuts experienced after its primary US listing.
• View this delisting primarily as a strategic alignment to consolidate its market presence and achieve minor cost efficiencies, with the company's fundamental performance in the US market remaining the paramount factor for investment consideration.